![]() "The safety and efficacy of Pradaxa and Praxbind are well-established and we look forward to sharing results from these new analyses, which we believe will provide further insight on the role these treatments can play for a range of patients."ĭetails of the data to be presented at the ACC 67 th Annual Scientific Session are as follows: ![]() "Boehringer Ingelheim is proud to continue its research in anticoagulation care to help better meet the diverse and evolving needs of both patients and healthcare providers," said Thomas Seck, M.D., vice president, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. The sub-analyses provide further data on the use of Pradaxa and Praxbind in a diverse group of patients, including non-valvular atrial fibrillation (NVAF) patients who have undergone percutaneous coronary intervention with stenting, patients with uncontrollable bleeding or needing an emergency procedure, and patients with acute deep vein thrombosis or pulmonary embolism. In total, six abstracts have been accepted examining the novel oral anticoagulant, Pradaxa® (dabigatran etexilate mesylate), and its specific reversal agent, Praxbind® (idarucizumab). ![]() RIDGEFIELD, Conn., Ma/PRNewswire/ - Boehringer Ingelheim today announced that important sub-analyses from three major trials will be presented at the American College of Cardiology (ACC) 67 th Annual Scientific Session, to be held March 10-12 in Orlando, Florida.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |